ABSTRACT In this study, the calcification and platelet adhesion resistance property of plasma-treated polyurethane/heparinised carbon nano tube (PU/HCNT) nanocomposite thin films as a candidate polymer for polymeric heart valve was investigated. The PU and HCNTs nanocomposite films (PU/HCNT) were prepared using the solvent casting technique. CNTs were heparinised to surpass the dispersal and calcification resistance of CNTs in the PU matrix. Dispersal of CNTs in the matrix of produced films was analysed with (TEM), and HCNTs were observed well distributed in the polymer matrix. Greater storage modulus and better calcification resistance were detected for the nanocomposite. DMTA used for determining nanocomposite properties, which showed that the modulus increased as modified CNTs added to the matrix. The composite films were exposed to oxygen plasma treatment. The modified surface was characterised using ATR-FTIR, SEM, EDXA, and water drop contact angle measurements. The results indicated that the treated PU/HCNT surface was more hydrophilic. Increased surface roughness for modified PU/HCNT surface observed in AFM images. In-vitro calcification test verified reduced calcification for the modified PU/HCNT surface. No cytotoxicity was observed for the modified polymeric films using L929 fibroblast cells. The platelet adhesion test showed that the modified films are more blood compatible than unmodified.

中文翻译：

---

肝素化 CNT/PU 纳米复合材料的等离子体改性和机械、钙化和血小板粘附特性的测量在心脏瓣膜中的应用

摘要 在本研究中，研究了等离子体处理的聚氨酯/肝素化碳纳米管 (PU/HCNT) 纳米复合薄膜作为聚合物心脏瓣膜的候选聚合物的钙化和抗血小板粘附性能。使用溶剂浇铸技术制备了 PU 和 HCNTs 纳米复合薄膜 (PU/HCNT)。碳纳米管被肝素化以超过碳纳米管在聚氨酯基质中的分散和钙化阻力。用（TEM）分析了碳纳米管在生产的薄膜基体中的分散情况，观察到 HCNTs 在聚合物基体中分布良好。检测到纳米复合材料具有更大的储能模量和更好的抗钙化性。DMTA 用于确定纳米复合材料的性能，这表明随着改性 CNT 添加到基质中，模量增加。复合膜暴露于氧等离子体处理。改性表面使用 ATR-FTIR、SEM、EDXA 和水滴接触角测量进行表征。结果表明，处理过的 PU/HCNT 表面更亲水。在 AFM 图像中观察到的改性 PU/HCNT 表面的表面粗糙度增加。体外钙化测试证实了改性 PU/HCNT 表面的钙化减少。对于使用 L929 成纤维细胞的改性聚合物膜，未观察到细胞毒性。血小板粘附试验表明，改性薄膜比未改性薄膜具有更好的血液相容性。在 AFM 图像中观察到的改性 PU/HCNT 表面的表面粗糙度增加。体外钙化测试证实了改性 PU/HCNT 表面的钙化减少。对于使用 L929 成纤维细胞的改性聚合物膜，未观察到细胞毒性。血小板粘附试验表明，改性薄膜比未改性薄膜具有更好的血液相容性。在 AFM 图像中观察到的改性 PU/HCNT 表面的表面粗糙度增加。体外钙化测试证实了改性 PU/HCNT 表面的钙化减少。对于使用 L929 成纤维细胞的改性聚合物膜，未观察到细胞毒性。血小板粘附试验表明，改性薄膜比未改性薄膜具有更好的血液相容性。